Karyopharm Therapeutics (NASDAQ:KPTI)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a report issued on Tuesday, BenzingaRatingsTable reports. They presently have a $37.00 target price on the stock, up from their previous target price of $36.00. HC Wainwright’s price objective points to a potential upside of 99.14% from the company’s current price.
Several other analysts also recently weighed in on the company. Wedbush lifted their target price on Karyopharm Therapeutics from $15.00 to $18.00 in a research report on Wednesday, November 6th. Robert W. Baird set a $25.00 target price on Karyopharm Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, September 24th. Bank of America upgraded Karyopharm Therapeutics from an “underperform” rating to a “neutral” rating in a research report on Friday, January 3rd. Zacks Investment Research upgraded Karyopharm Therapeutics from a “hold” rating to a “strong-buy” rating and set a $21.00 target price for the company in a research report on Tuesday. Finally, ValuEngine downgraded Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, December 3rd. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $22.14.
NASDAQ KPTI traded up $0.18 on Tuesday, hitting $18.58. 16,973 shares of the stock were exchanged, compared to its average volume of 1,081,840. The company has a debt-to-equity ratio of 2.03, a quick ratio of 7.16 and a current ratio of 7.16. The stock has a fifty day moving average price of $17.93 and a two-hundred day moving average price of $12.21. The firm has a market capitalization of $1.12 billion, a P/E ratio of -5.90 and a beta of 2.59. Karyopharm Therapeutics has a 52-week low of $3.92 and a 52-week high of $20.09.
Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings data on Monday, November 4th. The company reported ($0.67) EPS for the quarter, topping the consensus estimate of ($0.84) by $0.17. Karyopharm Therapeutics had a negative net margin of 909.24% and a negative return on equity of 187.25%. The company had revenue of $13.15 million during the quarter, compared to analyst estimates of $1.61 million. Sell-side analysts expect that Karyopharm Therapeutics will post -3.13 earnings per share for the current fiscal year.
In related news, Director Mansoor Raza Mirza sold 2,056 shares of Karyopharm Therapeutics stock in a transaction dated Thursday, January 9th. The stock was sold at an average price of $20.00, for a total value of $41,120.00. Following the completion of the sale, the director now directly owns 2,056 shares in the company, valued at $41,120. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Christopher Brett Primiano sold 5,000 shares of Karyopharm Therapeutics stock in a transaction dated Friday, December 27th. The shares were sold at an average price of $20.00, for a total value of $100,000.00. Following the completion of the sale, the executive vice president now owns 8,653 shares of the company’s stock, valued at $173,060. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 135,463 shares of company stock valued at $2,182,510. Corporate insiders own 13.26% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC raised its holdings in shares of Karyopharm Therapeutics by 536.6% in the third quarter. Tower Research Capital LLC TRC now owns 3,476 shares of the company’s stock valued at $34,000 after acquiring an additional 2,930 shares in the last quarter. Bank of Montreal Can bought a new stake in shares of Karyopharm Therapeutics in the second quarter valued at about $29,000. Virtu Financial LLC bought a new stake in shares of Karyopharm Therapeutics in the third quarter valued at about $99,000. Envestnet Asset Management Inc. raised its holdings in shares of Karyopharm Therapeutics by 12.4% in the second quarter. Envestnet Asset Management Inc. now owns 11,980 shares of the company’s stock valued at $72,000 after acquiring an additional 1,319 shares in the last quarter. Finally, Commonwealth Equity Services LLC bought a new stake in shares of Karyopharm Therapeutics in the third quarter valued at about $124,000. Hedge funds and other institutional investors own 93.14% of the company’s stock.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for
the treatment of cancer and other major diseases. Karyopharm’s SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1).
Featured Story: Why do commodities matter?
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.